Stock info Gilead Sciences | Filter  Basic-Info

Stock: Gilead Sciences (US Tech), ISIN: US3755581036

Last Price 107.20 Max Price 114.43
Min Price 67.55 1 Year return 0.00
Sector Health Care Subsector Biotechnology
Annual report 2020

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. Gilead Sciences' mission is to advance the care of patients suffering from life-threatening diseases worldwide. In addition to Gilead Sciences' marketed products, Gilead Sciences has a clinical, preclinical and research pipeline focused on developing anti-infectives. Gilead Sciences’ stocks are traded in New York and the company is a component of the NASDAQ 100-index (ISIN: US3755581036/ Symbol: GILD).

Loading...

Contact info:Street: Foster City, CA 94404Zip Code: CA 94404City: Foster CityCountry: USAPhone: (650) 5743000Email: investor_relations@gilead.comWebsite: www.gilead.comCEO: John C. MartinCFO: Robin L. Washington

Sector Review Gilead Sciences

Loading...
Year Turnover Total sector Market share
2019 20,025 135,969 14.73 %
2020 20,215 152,939 13.22 %
2021 24,019 227,396 10.56 %
2022 25,491 260,129 9.80 %
2023 24,570 214,794 11.44 %

Advice Gilead Sciences

Date Label Bank Label Stock Label Advice Label Price Label Diff Label
November 03, 2020 Morgan Stanley Gilead Sciences Hold 67.00 6.66 %
September 15, 2020 RBC Capital Markets Gilead Sciences Hold 82.00 23.73 %
August 19, 2020 Jefferies & Co. Gilead Sciences Buy 78.00 19.82 %
August 19, 2020 Robert W. Baird Gilead Sciences Buy 70.00 10.66 %
August 19, 2020 Credit Suisse Gilead Sciences Hold 70.00 10.66 %
May 04, 2020 KBC Securities Gilead Sciences Hold 82.00 23.73 %
April 30, 2020 ABN AMRO Gilead Sciences Hold 83.00 24.65 %
April 20, 2020 BMO Capital Markets Gilead Sciences Hold 78.00 19.82 %
April 20, 2020 Wells Fargo Gilead Sciences Hold 87.00 28.11 %
February 06, 2020 Cowen and Company Gilead Sciences Buy 80.00 21.82 %
February 06, 2020 Raymond James Gilead Sciences Buy 80.00 21.82 %
February 06, 2020 RBC Capital Markets Gilead Sciences Hold 86.00 24.30 %
February 06, 2020 Jefferies & Co. Gilead Sciences Buy 76.00 14.34 %
February 05, 2020 KBC Securities Gilead Sciences Buy 82.00 20.61 %
January 09, 2020 RBC Capital Markets Gilead Sciences Hold 89.00 30.39 %
October 28, 2019 RBC Capital Markets Gilead Sciences Hold 67.00 9.27 %
October 28, 2019 Raymond James Gilead Sciences Buy 81.00 24.95 %
October 28, 2019 BMO Capital Markets Gilead Sciences Hold 81.00 24.95 %
August 01, 2019 JP Morgan Gilead Sciences Buy 85.00 26.42 %
August 01, 2019 Credit Suisse Gilead Sciences Hold 67.00 -4.61 %
August 01, 2019 Raymond James Gilead Sciences Buy 86.00 18.50 %
August 01, 2019 BMO Capital Markets Gilead Sciences Hold 82.00 14.52 %
July 15, 2019 Wells Fargo Gilead Sciences Buy 88.00 11.94 %
May 28, 2019 Goldman Sachs Gilead Sciences Sell 60.00 -4.23 %
May 24, 2019 Citigroup Gilead Sciences Buy 78.00 19.82 %
May 23, 2019 Citigroup Gilead Sciences Buy
May 21, 2019 Credit Suisse Gilead Sciences Hold 70.00 -6.80 %
May 07, 2019 Raymond James Gilead Sciences Buy 83.00 4.65 %
May 07, 2019 Leerink Swann & Company Gilead Sciences Hold 78.00 19.82 %
May 07, 2019 JP Morgan Gilead Sciences Buy 87.00 9.03 %
May 07, 2019 RBC Capital Markets Gilead Sciences Hold 91.00 13.03 %
February 13, 2019 RBC Capital Markets Gilead Sciences Hold 84.00 18.48 %
February 13, 2019 Wells Fargo Gilead Sciences Buy 68.00 -0.71 %
February 13, 2019 Citigroup Gilead Sciences Hold 75.00 8.69 %
February 13, 2019 Raymond James Gilead Sciences Buy 85.00 19.44 %
February 12, 2019 KBC Securities Gilead Sciences Hold 82.00 16.49 %
February 06, 2019 Raymond James Gilead Sciences Buy 90.00 26.92 %
February 06, 2019 Morgan Stanley Gilead Sciences Hold 83.00 20.76 %
February 05, 2019 RBC Capital Markets Gilead Sciences Hold 89.00 25.44 %
February 05, 2019 KBC Securities Gilead Sciences Hold 87.00 23.72 %



News Gilead Sciences

Gilead Sciences in top American dividend stocks

00For this year the analysts expect a dividend of 3.13 USD per share. Thus the dividend yield equals 4.67 percent. The average dividend yield of the biotech companies equals an attractive 3.55 percent. Historical dividend returns Gilead Sciences Tomorrowthe...

FDA puts partial clinical hold on Gilead's magrolimab + azacitidine studies

Gilead Sciences (NASDAQ:GILD) announces that the FDA has placed a partial clinical hold on studies evaluating the combination of magrolimab plus azacitidine due to an apparent imbalance in suspected unexpected serious adverse reactions (SUSARs) between study...

Gilead and Merck ink collaboration agreement for Keytruda/Trodelvy breast cancer study

Gilead Sciences (NASDAQ:GILD) has entered into a clinical trial collaboration and supply agreement with Merck KGaA (NYSE:MRK) to evaluate the efficacy of Trodelvy in combination with Keytruda as a first-line treatment for certain patients with triple-negative...

Gilead and Novo Nordisk expand collaboration in NASH therapeutics

Gilead Sciences (NASDAQ:GILD) and Novo Nordisk (NYSE:NVO) have announced an expansion of their clinical collaboration in non-alcoholic steatohepatitis ('NASH"). The two companies have agreed to conduct a Phase 2b study to investigate the safety and efficacy...

Gilead Sciences now in top highest dividend yields in America

Investors in Gilead Sciences can expect a huge dividend payment. Based on the recent analysts' consensus the stock now has one of the highest dividend returns of the American market. Per share the analysts anticipate on a dividend of 2,7 USD per share. The dividend...

Annual reports Gilead Sciences

2017 2018 2019 2020 2021

Profile Gilead Sciences

Gilead Sciences

(US3755581036)/ GILD

Gilead Sciences has located her head office Foster City. Gilead Sciences mainly operates in the biotech sector. John C. Martin manages the company as a CEO. The CFO of Gilead Sciences the company is Robin L. Washington. The global biotech companies gained around 59 percent over the period 2006-2016. Since 2011 the sector is 70 percent higher and over the past year minus 59 percent.

The past year was a good year for Gilead Sciences investors

Over the last 12 months, that were loss-making period for the investors in Gilead Sciences, the stock lost around 28 percent. Over the period from December 2011 till December 2016 the stock rose on average 280 percent. Gilead Sciences's revenues between 2011 and 2015 were very volatile through the time and moved between 9,7 billion dollars and 32,64 billion dollars. Gilead Sciences's net incomes between 2011 and 2015 were very volatile and moved between 2,79 billion dollars and 18,11 billion dollars.

Gilead Sciences paid out dividends in the past 5 years. Over the past 5 years the stock delivered an average dividend return of 1,29 percent.

Gilead Sciences had about 7000 thousand employees at the end of 2015.

Gilead Sciences' balance mostly consists of equity

At the end of 2015 the American company had a balance sheet of around 51,84 billion dollars. The total debt of the biotech company was at the end of 2015 33,31 billion dollars, which equals around 64,25 percent of the total balance sheet. At the end of 2016 the American company was traded with a price/earnings-ratio of around 8. So investors paid 8 times the company's 2015's EPS. Based on the classical stock valuation theories the American stock can be seen as a value stock.

The biotech company's market capitalization (the number of shares outstanding times the market value) equaled around 139,71 billion dollars. At the end of 2015 around 1,42 billion stocks were listed.

On this page you can find all Gilead Sciences's financial reports. More information about Gilead Sciences can be found it's website. .


Results Gilead Sciences

Results
2015
2016
2017
2018
2019
2020
Revenue
30,054
28,906
21,763
19,292
20,025
20,215
Costs
13,380
16,064
17,906
14,536
15,221
20,115
Profit
16,674
12,842
3,857
4,756
4,804
100
Margin of profit
55.48
44.43
17.72
24.65
23.99
0.49
ROI
97.70
71.48
22.63
25.51
23.91
0.67

Balance Gilead Sciences

Balance
2015
2016
2017
2018
2019
2020
Equity
17,066
17,965
17,040
18,647
20,093
14,903
Debt
30,554
36,231
41,548
36,872
34,881
41,108
Total assets
47,620
54,196
58,588
55,519
54,974
56,011
Solvency
35.84
33.15
29.08
33.59
36.55
26.61
Cash
13,451
11,314
21,265
26,235
21,723
6,065
Cashflow
19,567
16,215
9,918
7,324
8,157
6,687
Employees
0
0
0
0
0
Revenue per employee
0.0
0.0
0.0
0.0
0.0
Cashflow / Debt
0.64
0.45
0.24
0.20
0.23
0.16

Details Gilead Sciences

Details
2016
2017
2018
2019
2020
Price
101.19
71.61
71.64
62.55
64.98
Eps
9.00
2.00
3.00
3.00
Price/earnings-ratio
11.24
35.80
23.88
20.85
Dividend
1.00
1.00
1.00
2.00
2.00
Dividend %
0.99 %
1.40 %
1.40 %
3.20 %
1.87 %
Payout %
0.11
0.50
0.33
0.67
Book value
13.75
13.03
14.55
15.87
11.88
Market to book
0.14
0.18
0.20
0.25
0.11
Cashflow per stock
12.41
7.58
5.71
6.44
5.33
Stocks
1,307
1,308
1,282
1,266
1,254
Market Cap
132.255.33
93.665.88
91.842.48
79.188.30
134.428.80

Dividend Gilead Sciences


Price info Gilead Sciences

Date
Price
25 Jun 2025
107.20
20 Jun 2025
108.00
07 Jun 2025
112.46
03 Jun 2025
108.91
28 May 2025
109.09
27 May 2025
107.37
19 May 2025
102.50
09 May 2025
98.16
01 May 2025
106.54
29 Apr 2025
106.34
22 Apr 2025
104.33
09 Apr 2025
105.52
08 Apr 2025
105.52
03 Apr 2025
111.89
30 Mar 2025
111.79
27 Mar 2025
109.27
26 Mar 2025
107.89
20 Mar 2025
107.51
15 Mar 2025
111.44
12 Mar 2025
114.43
01 Mar 2025
114.31
25 Feb 2025
111.03
23 Feb 2025
109.95
18 Feb 2025
104.08
13 Feb 2025
103.31
12 Feb 2025
96.14
07 Feb 2025
98.04
05 Feb 2025
97.99
02 Feb 2025
97.20
21 Jan 2025
91.84